Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.
Learn More
Alfa Cytology possesses extensive experience and advanced technology in the field of drug testing, offering top-quality testing services for leukemia drugs. Our Leukemic colony-forming cell (CFC) Assays accurately assess the impact of drugs by measuring changes in the number of colonies derived from cancer progenitor cells. This analysis enables the evaluation of drug efficacy. Our CFC analysis service aids in the identification of potential candidates with notable drug effects while excluding participants who may not benefit from the treatment.
Hematopoietic stem cells or progenitor cells are derived from sources such as bone marrow, umbilical cord blood, or peripheral blood. These cells possess the remarkable ability to differentiate into both myeloid and lymphoid cells. Due to their unique properties, hematopoietic stem cells are widely utilized in the study of hematopoiesis and leukemia. The colony-forming cell assay is a commonly employed method that leverages the capability of hematopoietic progenitor cells to form colonies in a semi-solid medium. Importantly, it serves as an effective tool for evaluating drugs that inhibit the growth of hematological cancer stem cells and progenitor cells.
With the support of our highly skilled biotechnology team, we offer comprehensive services for leukemia research. We provide CFC assays to evaluate the effectiveness of drugs used in the treatment of leukemia, as well as assess their toxicity.
Utilizing the identification of distinct progenitor cell lineages, we assess the lineage-specific effects of leukemia drugs. Our analysis involves evaluating the inhibitory potential of candidate drugs on the proliferation of hematological cancer stem cells and progenitor cells, as well as predicting potential hematotoxicity. These findings hold significant reference value in determining the maximum tolerated dose (MTD) of the drugs under investigation.
| Granulocyte macrophage | We provide toxicity prediction for single drugs or combination therapies on bone marrow cells. This analysis helps to anticipate potential adverse effects on bone marrow function. |
| Megakaryocyte | Our services include evaluating the toxicity of single drugs or combination therapies specifically on megakaryocytes. This assessment aids in understanding the potential impact on megakaryocyte function and platelet production. |
| Erythroid | We assess the toxicity of single drugs or combination therapies on erythroid cells. This evaluation provides valuable insights into potential effects on erythropoiesis and red blood cell production. |
| Pre-B Lymphocyte | We predict the lymphatic toxicity caused by single drugs or combination therapies. This analysis helps identify potential adverse effects on lymphatic cells and lymphoid tissue. |
We offer a comprehensive leukemic CFC assay service aimed at identifying leukemia colony-forming cells. In cases where morphological identification alone is challenging, we provide additional tests to enhance result accuracy, ensuring precise experimental outcomes for leukemia colony-forming cells. These supplementary tests encompass flow cytometry, fluorescence in situ hybridization, and molecular analysis. The scope of our analysis extends to various types of leukemia, including but not limited to the following:
With our extensive experience in CFC assay, Alfa Cytology is the perfect partner for your research needs. You can have full confidence in our ability to deliver precise experimental results, ultimately saving you valuable research time and expediting the clinical translation process. Contact us to discuss your specific requirements and explore the wide range of testing options we can provide for you.